13078-91-6

Basic information

• Product Name: 2-(Indolin-3-yl)ethanaMine
• Synonyms: 2-(Indolin-3-yl)ethanaMine;2,3-dihydro-1H-Indole-3-ethanaMine;2-(Indolin-3-yl)
• CAS NO: 13078-91-6
• Molecular Formula: C₁₀H₁₄N₂
• Molecular Weight: 162.23156
• Mol File: 13078-91-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 280°C at 760 mmHg
• Flash Point: 142.8°C
• Appearance: /
• Density: 1.041g/cm³
• Vapor Pressure: 0.00388mmHg at 25°C
• Refractive Index: 1.555
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.04±0.10(Predicted)
• CAS DataBase Reference: 2-(Indolin-3-yl)ethanaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Indolin-3-yl)ethanaMine(13078-91-6)
• EPA Substance Registry System: 2-(Indolin-3-yl)ethanaMine(13078-91-6)

Safety Data

• Hazardous Substances Data: 13078-91-6(Hazardous Substances Data)

Usage

Description

2-(Indolin-3-yl)ethanamine, also known as 2-IEA, is a chemical compound with a molecular formula C10H11N. It is an organic compound that contains an indoline ring and an amine group, making it a derivative of the neurotransmitter serotonin. Its unique structure and pharmacological properties make it a promising candidate for therapeutic applications in various conditions.

Uses

Used in Pharmaceutical Industry:
2-IEA is used as a therapeutic agent for various conditions, including depression, anxiety, and drug addiction. Its ability to modulate neurotransmitter levels and receptor activity makes it a potential treatment option for these disorders.
Used in Neuroscience Research:
2-IEA is used as a research tool in neuroscience to study the effects of serotonin and its derivatives on the central nervous system. Its structural similarity to serotonin allows researchers to investigate the mechanisms of action and potential therapeutic applications of this compound.
Used in Drug Discovery:
2-IEA is used as a lead compound in drug discovery for the development of new medications targeting the serotonergic system. Its potential as a dopaminergic agent and potential treatment for Parkinson's disease highlights its versatility and potential for further research and development.
Used in Chemical Synthesis:
2-IEA can be used as a building block or intermediate in the synthesis of other organic compounds, particularly those with potential pharmaceutical or chemical applications. Its indoline ring and amine group provide opportunities for further functionalization and modification to create new molecules with desired properties.

InChI:InChI=1/C10H14N2/c11-6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,8,12H,5-7,11H2

Upstream product

• 19260-03-8 1-(1H-indol-3-yl)-N,N,N-trimethylmethanaminium methyl sulfate 
• 61-54-1 tryptamine 
• 771-51-7 indole-3-acetonitrile 

Downstream Products

• 193551-50-7 (2-bromophenyl)-(9H-β-carbolin-1-yl)-methanone 
• 169129-61-7 Benzhydrylidene-[2-(2,3-dihydro-1H-indol-3-yl)-ethyl]-amine 
• 907969-24-8 tert-butyl N-(2-indolin-3-ylethyl)carbamate 
• 82575-82-4 N-2-(indol-3-yl)ethyl-indole-3-acetamide 
• 169129-62-8 Benzhydrylidene-{2-[1-(toluene-4-sulfonyl)-2,3-dihydro-1H-indol-3-yl]-ethyl}-amine 
• 169129-63-9 2-[1-(Toluene-4-sulfonyl)-2,3-dihydro-1H-indol-3-yl]-ethylamine 

Relevant articles and documents

FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS

The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease.

Nucleophilic substitution reaction of N-2-(1-hydroxyindol-3-yl)ethylindole-3-acetamide and -1-hydroxyindole-3-acetamide

Syntheses of N-2-(1-hydroxyindol-3-yl)ethyl-1-hydroxyindole-3-acetamide (3a) and -indole-3-acetamide (4a) are reported. They undergo nucleophilic substitution reaction at the 1-position upon reaction with indole in 85% formic acid to give new type compounds, N-2-[1-(indol-3-yl)indol-3-yl]ethylindole-3-acetamide (13), N-2-(indol-3-yl)ethyl-(14), and N-2-[1-(indol-3-yl)indol-3-yl]ethyl-1-(indol-3-yl)indole-3-acetamide (15).

Cardiac-Slowing Amidines Containing the 3-Thioindole Group. Potential Antianginal Agents

A series of 3-thioindolamidines (and 3-indolamidines) related to mixidine (1) was studied for cardiac-slowing properties, allowing the discovery of activity for prototype thioindole 2.Structure-activity relationships were explored, leading to many potent antitachycardic agents (6-9, 12, 13, 15-17, 20, 23, 24, 30, 34, 35, 45, and 47-49).Relative to 2, cardiac-slowing activity is enhanced by substitution of the indole nitrogen with small (C1-C3) saturated alkyl groups (6-9), unsaturated alkyl groups (12, 13, and 15-17), or a methoxyethyl group (20); replacement of the N-methyl group with alkyl (23) or phenyl groups (24); and extension of the ethylene bridge by two methylene units (34).Dethio (i.e., 3-indole) analogues of 2 with alkyl substitution on the indole nitrogen (47-49) have greater activity as well.Several potent compounds were also found to have minimal myocardial depression (6-9, 13, 45, and 47).Secondary pharmacological testing is reported for thioindoles 2, 6, 7, 9, and 28.